Biotechnology firm Biocon today said its partner Mylan has re-submitted marketing authorisation applications with the European drug regulator European Medicines Agency for two biosimilars Trastuzumab and Pegfilgrastim.
"Biocon's partner Mylan has resubmitted the marketing authorisation applications (MAAs) for our proposed biosimilar trastuzumab and pegfilgrastim with the European drug regulator European Medicines Agency (EMA) as per administrative protocol," the company said in a regulatory filing.
The company said this follows earlier withdrawal of both the applications in response to observations made by the European regulator.
"Biocon has completed the corrective and preventive actions (CAPAs), including the facility modifications, in response to the audit observations and expects these to be verified during re-inspection," it added.
Shares of Biocon were trading 0.23 per cent higher at Rs 413 in the morning trade on the BSE today.
Disclaimer: No Business Standard Journalist was involved in creation of this content
